Are more courses of immunochemotherapy beneficial for the short‐term outcome of locally advanced esophageal squamous cell carcinoma?

Author:

Huang Yuanheng123ORCID,Su Xiaodong123ORCID,Guo Qiyu123,Luo Guangyu14,He Haoqiang15,Cai Peiqiang15,Cai Muyan16,Yue Haodong16,Wang Zhiqiang17,Yang Guozhen123,Lin Peng123,Zhang Xu123

Affiliation:

1. State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangzhou China

2. Department of Thoracic Oncology Sun Yat‐sen University Cancer Center Guangzhou China

3. Guangdong Esophageal Cancer Institute Guangzhou China

4. Department of Endoscopy Sun Yat‐sen University Cancer Center Guangzhou China

5. Department of Medical Imaging and Interventional Radiology Sun Yat‐sen University Cancer Center Guangzhou China

6. Department of Pathology Sun Yat‐sen University Cancer Center Guangzhou China

7. Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou China

Abstract

AbstractBackgroundImmune checkpoint inhibitor (ICI) monotherapy and neoadjuvant immunochemotherapy have shown promising results in esophageal carcinoma. However, it is still unclear whether more courses of immunochemotherapy are therapeutically better. We aimed to investigate the safety and efficacy of three courses of neoadjuvant treatment for patients with locally advanced esophageal squamous cell carcinoma (ESCC).MethodsPatients with locally advanced ESCC received three courses of camrelizumab plus nab‐paclitaxel and capecitabine before undergoing surgery. Additionally, patients received safety, computed tomography (CT), and endoscopy (with endoscopic ultrasonography and mucosal biopsy) assessments before and in the second and third courses of treatment. We used the CT and endoscopic assessment results from the second and third courses for comparison.ResultsFrom May 2020 to December 2021, 47 patients were enrolled at Sun Yat‐sen University Cancer Center. In our study, 43 patients completed three courses of preoperative chemotherapy combined with anti‐Programmed cell death‐1 (PD‐1) therapy and radical surgical resection. The toxicity of the third course of immunochemotherapy was mild and well tolerated without increased treatment‐related adverse events (TRAEs) and mortality compared with that of the second course of treatment. In terms of efficacy, an additional course of treatment after the second course of treatment was effective, with increased CT and endoscopy T (clinical T stage) downstaging rates by 16.3% and 25.9%, N (clincial N stage) downstaging rates by 7.0% and 11.1%, and objective response rates (ORRs) by 13.6% and 22.0%, respectively.ConclusionsRegardless of downstaging or ORR, three courses of immunochemotherapy appear to be superior to two courses of treatment without increasing TRAEs.

Funder

Guangdong Esophageal Cancer Research Institute

Guangzhou Science and Technology Program key projects

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3